1.Anaysis of 268 Cases of Phlegm-dampness Syndrome of PCOS with Hyperandrogenism
Meiwei ZHANG ; Lihui HOU ; Ying WANG
Journal of Medical Research 2018;47(5):70-73
Objective Through the collection and analysis of clinical features and biochemical indices data got from 436 women who were diagnosed as phlegm-dampness syndrome of PCOS,in order to provide the reference for the personalized treatment for disease and prevention of long-term complication.Methods We collected 436 cases of patients diagnosed with phlegm-dampness syndrome of PCOS and 62 cases of control group from December 2014 to August 2017.We analysied and compared of three groups of clinical and biochemical indicators.Results The incidence of hirsutism,acanthosis nigricans and excessive fat of phlegm-dampness syndrome of PCOS + HA subgroup were higher than phlegm-dampness syndrome of PCOS + non-HA subgroup(P < 0.05).The LH and LH/FSH of of phlegm-dampness syndrome of PCOS + HA subgroup were higher.The level of FSH and SHBG was lower than phlegm-dampness syndrome of PCOS + non-HA subgroup and the control group(P < 0.05).The TC,TG and LDL of phlegm-dampness syndrome of PCOS + HA subgroup were higher than phlegm-dampness syndrome of PCOS + non-HA subgroup and the control group(P < 0.05).The FPG,FINS and HOMA-IR of phlegm-dampness syndrome of PCOS + HA subgroup is higher than phlegm-dampness syndrome of PCOS +non-HA subgroup and the control group(P < 0.05).Conclusion The patients with phlegm-dampness syndrome of PCOS + HA have higher incidence of hirsutism,acanthosis nigricans and excessive fat.The patients with phlegm-dampness syndrome of PCOS + HA have serious sex hormone metabolic disorders.The patients with phlegm-dampness syndrome of PCOS + HA have serious glucolipid metabolic disorders.
2.MRI and diffusion-weighted imaging in the diagnosis of autoimmune pancreatitis
Yuexi CHEN ; Guozhao LI ; Xiang ZHANG ; Xiaohui DUAN ; Fang ZHANG ; Liejing LU ; Meiwei CHEN ; Kun ZHAO ; Yueyao CHEN ; Jun SHEN
Chinese Journal of Hepatic Surgery(Electronic Edition) 2015;(1):42-45
Objective To investigate the value of magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of autoimmune pancreatitis (AIP). Methods Clinical data of 11 patients pathologically diagnosed with AIP in Sun Yat-sen Memorial Hospital, Sun Yat-sen University from January 2013 to June 2014 were analyzed retrospectively. There were 7 males and 4 females with a mean age of (54±15) years old. The informed consents of all patients were obtained and local ethical committee approval had been received. Apparent diffusion coefifcient (ADC) of the pancreatic lesions was measured by MRI scan, multiphase dynamic enhanced scan and DWI. The imaging features of AIP by MRI and DWI were observed. Results The AIP lesions displayed iso-or slightly hypo-intense signal on T1WI and slightly hyper-intense signal on T2WI by MRI and continuous gradual enhancement by multiphase dynamic enhanced scan. The average ADC of the lesions by DWI was (1.09±0.09)×10-3 mm2/s and the pancreatic lesions displayed high signal. Diffusely swelling pancreas with plump shape, sausage-like appearance was observed in 7 cases. Local mass were observed at the pancreatic head in 3 cases. Mass in the pancreatic body and tail was observed in 1 case. Capsule-like ring-like shadow was observed around the pancreas in 6 cases by MRI and iso-or slightly hypo-intense signal on T1WI and slightly lower-or hyper-intense signal on T2WI were observed. No enhancement or hypo-enhancement was observed in arterial phase by multiphase dynamic enhanced scan. Delayed enhancement was observed in delayed phase. The enhancement degree was mildly lower than that of pancreatic parenchyma. Multiple enlarged lymph nodes were observed around the pancreas and at the retroperitoneum in 4 cases. Conclusions MRI is useful for the diagnosis of AIP. The dynamic enhanced scan and DWI ifndings can be used as the direct images for diagnosing AIP and have a high clinical reference value.
3.Research on the standardization of “Indications”in package inserts for Chinese patent medicines
Meiwei ZHANG ; Keqian LI ; Keyu YAO ; Yan ZHU
China Pharmacy 2025;36(5):513-518
OBJECTIVE To promote the standardization of the “Indications” section in package inserts for Chinese patent medicines and ensure rational clinical and patient use. METHODS The “Function and Indications” information of package inserts for Chinese patent medicines was retrieved and collected from the 2020 edition of the Chinese Pharmacopoeia (Volume Ⅰ) and various national and regional standards. Identification criteria were established for syndrome, pathogenesis, disease name, and symptom terminology in the “Indications” section. Microsoft Office Access 2021 was utilized to create query tables for manual extraction of terminological elements, followed by the construction of a three-tier classification system for “Indications” descriptions. A standardized template for “Indications” was developed through quantitative analysis. RESULTS & CONCLUSIONS A total of 9 851 valid package inserts for Chinese patent medicines were included. Among these, the majority (7 991) contained symptom terminology, followed by disease names (5 867) and pathogenesis descriptions (5 167). Within disease name terminology, Western medical disease names predominated (4 446), followed by traditional Chinese medicine disease names (2 018). The “Function and Indications” content of 6 962 package inserts complied with existing requirements. Notably, the secondary classifications of “disease name”, as well as the tertiary classification of “disease name+symptoms” and “symptoms”, failed to meet established standards. Two standardized templates for “Indications” were formulated based on pathogenesis and syndrome:“pathogenesis+disease name+symptoms” and “disease name+syndrome+symptoms”. The “Indications”section should provide complete and accurate information, adhere to standardized formatting, and employ appropriate conjunctions and punctuation. For non-prescription patent medicines, package inserts should be categorized into professional and patient versions. These measures will facilitate the standardization of “Indications” descriptions and advance the overall package inserts for Chinese patent medicines documentation.
4.An Overview of Fermentation Technology Evolution and Process Control of Sojae Semen Praeparatum
Wang-min LIN ; Qian-qian WENG ; Ai-ping DENG ; Jia-chen ZHAO ; Yue ZHANG ; Hai-yang WANG ; Ya-feng REN ; Shui-li ZHANG ; Bing YU ; Zhi-lai ZHAN ; Lu-qi HUANG
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(11):222-232
The historical evolution, fermentation technology and key links of Sojae Semen Praeparatum (SSP) were sorted out by consulting ancient books and modern literature, and the influencing factors and control methods of quality were analyzed and summarized in order to provide reference for the quality control of SSP. After analysis, it was found that in the fermentation process of SSP, fermentation strains, miscellaneous bacteria, temperature and humidity were all important factors affecting the quality of SSP. The condition control of "post fermentation" process has been paid more attention to in the past dynasties. In addition, the delicious SSP recognized in ancient times should be made from mold fermentation, and the breeding and application of fermented mold may be the key point to solve the quality problem of SSP. Therefore, based on the evaluation indexes of SSP in the past dynasties, it is of great significance to study and optimize the technological conditions such as strain, temperature and humidity in depth to improve the quality of SSP.